The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
Paper No. 12
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte NATESAN MURUGESAN, JOHN T. HUNT
and PHILIP D. STEIN
__________
Appeal No. 2002-0522
Application No. 09/552,543
__________
ON BRIEF
__________
Before WINTERS, WILLIAM F. SMITH, and GRIMES, Administrative Patent
Judges.
GRIMES, Administrative Patent Judge.
DECISION ON APPEAL
This is a decision on appeal under 35 U.S.C. § 134 from the examiner’s
final rejection of claims 23, 24, 26, and 27. Claims 25 and 28 are also pending;
the examiner has indicated that these claims would be allowable if rewritten in
independent form. See Paper No. 3, mailed October 2, 2000, page 3.
Claim 23 is representative and reads as follows:
23. A pharmaceutical composition comprising at least one endothelin
antagonist in combination with at least one additional therapeutic agent selected
from ECE inhibitors, PAF antagonists, AII receptor antagonists, renin inhibitors,
ACE inhibitors, NEP inhibitors, HMG CoA reductase inhibitors, squalene
synthetase inhibitors, bile acid sequestrants, calcium channel blockers,
Page: 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007